Viking Topline Ph2b VK2809 NASH Data; Chinook and Ionis Partner to Develop ASO Therapy for CKD

Two cardiometabolic-related news items have been observed: Viking Therapeutics announced positive topline results from its Ph2b VOYAGE study evaluating VK2809, an oral thyroid beta receptor (TRβ) agonist, in patients with biopsy-confirmed NASH (F2 and F3; view CT.gov record) and hosted an associated call with investors (view press release; webcast); and Chinook Therapeutics announced it has entered into a collaboration agreement with Ionis for the discovery, development, and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe CKD with significant unmet medical need (view press release). Below, FENIX provides highlights and insights into the respective news items.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.